MedTrace Logo

Effect of Paricalcitol Over Vessel Wall

NCT02372695 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-02-26

No results posted yet for this study

Summary

To provide evidence based prospectives of the potential benefit effects of paricalcitol, an analog of vitamin D, over the prevention / retardation of the progression of neoangiogenesis (vessels), atherosclerosis and vascular calcification.

Conditions

  • Nephropathy

Interventions

DRUG

Paricalcitol

Sponsors & Collaborators

  • Jaume Arnó Renal Foundation

    collaborator OTHER

  • Effice Servicios Para la Investigacion S.L.

    lead INDUSTRY

Principal Investigators

  • Maria Vittoria Arcidiacono, Ph D · Hospital Universitario Arnau de Vilanova de Lleida.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-05-31
Completion
2013-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02372695 on ClinicalTrials.gov